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ABSTRACT 
Objective:  Malignant astrocytomas are the most aggressive tumors affecting the brain. The natural history of 
survival of malignant astrocytomas differs significantly between anaplastic astrocytoma and glioblastoma 
multiforme (1). The clinical risk factors affecting the survival of malignant astrocytomas are scarcely studied (2). 
The aim of this study is to describe the clinical risk factors affecting the survival of malignant astrocytomas at 
king abdulaziz university hospital in Jeddah. 
Materials and Method:  From January 2004 to December 2008, medical files of patients with a diagnosis of 
anaplastic astrocytoma and glioblastoma multiforme were retrospectively reviewed. Only those with 
characteristic pathologic findings suggestive of malignant astrocytomas were enrolled. Demographic data and 
clinical manifestations with outcome were analyzed. All data were processed using SPSS 16 software (SPSS Inc., 
Chicago Illinois).The data were analysed for age, symptoms, signs and clinical risk factors influencing the 
survival of both tumours. Differences with p < 0.05 were considered significant. 
Results:  Forty eight cases were evaluated. The number of anaplastic astrocytoma was 15 (31.25%) and the 
number of GBM was 33 (68.75%). The mean age for glioblastoma multiforme was 55.3 ± 27.5 years. The mean 
age of anaplastic astrocytoma was 27.4 ± 21.3 years. Risk factors that worsen the prognosis were: A- old age p = 
.00002, B- Vomiting p < .02, C- Numbness p < .0001, D- Cranial nerves abnormalities p < .0004 and E- Abnor-
mal mental status p < .003. 
Conclusion:  Clinical risk factors affecting the survival negatively of patients with malignant astrocytomas are 
age, presentation with vomiting, numbness, abnormal mental status and abnormal cranial nerves examination. 
Keywords:  Anaplastic astrocytoma, glioblastoma multiforme, clinical, risk factors, Jeddah, Saudi Arabia. 
Abbreviations:  Anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), clinical risk factors, Malignant 
astrocytoma (MAS). 
 
INTRODUCTION 
Astrocytomas are brain tumors that originate from the 
glial cells. They represent a wide variety of tumors, 
ranging from benign tumors to malignant tumors. 
WHO classification for astrocytomas is a widely used 
system. It is based on the pathological features of the 
tumors (cell proliferation, mitosis, nuclear atypia and 
neovasculization). Grade I is a benign tumor (such as 
pilocytic astrocytoma) where there is cell proliferation 
only with no malignant features. Grade II is a benign 
tumor (such as fibrilary astrocytoma) where there are 
two neoplastic features. Grade III is a malignant 
tumor (such as anaplastic astrocytoma “AA”) where 
there are three neoplastic features. Grade IV is the 
most malignant tumor (glioblastoma multiforme 
“GBM”) where there are all four features of the malig-
nant neoplasm. Malignant astrocytomas (MAS) refer 
to the grades III and IV. 
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 Anaplastic astrocytoma (AA) represents about 
4.3% of all brain tumors. While glioblastoma multi-
forme (GBM) represents about 22.6% of all brain 
tumors (3). 
 The natural history of survival of MAS differs 
significantly between AA and GBM ranges from two 
months to eight years.
1
 
 The outcome of astrocytoma varies, where it is 
favorable for benign types and fatal for the malignant 
types. The treatment options for MAS are surgery, 
chemotherapy and radiotherapy. The Prognosis is 
influenced by age, symptoms’ duration, mental status 
and performance status. A truly complete resection, 
which is a recognized independent prognostic factor, is 
not possible and recurrence in the surgical cavity is 
common.
4
 The clinical risk factors affecting the survi-
val of MAS are scarcely studied.
2
 
 The aims of this study are (a) to describe the clini-
cal features of malignant astrocytoma and (b) to des-
cribe the clinical risk factors affecting the survival of 
malignant astrocytoma at king abdulaziz university 
hospital (KAUH) in Jeddah. 
 
MATERIALS AND METHOD 
From January 2004 to December 2008, medical files 
of patients with a diagnosis of anaplastic astrocytoma 
(AA) and glioblastoma multiforme (GBM) were retro-
spectively reviewed. Only those with characteristic 
pathologic findings and radiological features sugges-
tive of MAS were enrolled. Demographic data and cli-
nical manifestations were reviewed and analyzed. The 
outcome was recorded. 
 
Pathology Specimen 
The pathologic diagnosis included 33 GBMs and 15 
AA. The diagnosis was determined with specimens 
removed at surgical resection or biopsy, according to 
the WHO criteria, by general pathologists at KAUH. 
The specimens were obtained from both enhanced and 
non-enhanced areas of each tumor with reference to 
three-dimensional contrast material – enhanced MR 
images by using a neuro-navigational system (Brain 
Lab Vector Vision neuronavigation system, Germany) 
during surgery or biopsy. Routine histo-pathological 
tests were done (hematoxylin and eosin) and special 
immune-histochemistry studies (GFAP and Ki-67 / 
MIB-1) for all patients. 
Postoperative Treatment 
After surgery, all the patients subsequently received 
radiation therapy according to the protocol of our hos-
pital. For AAs, local brain irradiation of 72 Gy for 30 
days (5 days a week for 6 weeks) was delivered with 
the hyperfractionation method (1.2 Gy delivered 
twice a day). For GBM, whole-brain irradiation of 30 
Gy for 15 days (5 days a week for 3 weeks) was deli-
vered with the conventional method, and afterward, 
localized irradiation of 30 Gy for 10 days (5 days a 
week for 2 weeks) was delivered with the accelerated 
hyperfractionation method (1.5 Gy delivered twice a 
day). All the patients were evaluated at monthly out-
patient examinations. 
 
Statistical Analysis 
All collected data were processed using SPSS 16 soft-
ware (SPSS Inc., Chicago Illinois). The data were 
summarized as the mean ± standard deviation unless 
otherwise indicated. Univariate analysis of pooled data 
was performed with the Student t test and Wilcoxon 
rank-sum (Mann – Whitney test) for continuous para-
metric and nonparametric variables, respectively, and 
the χ2 test (or Fisher exact test) for categorical vari-
ables. The correlation was made between the age, cli-
nical presentation, treatment and the outcome using 
Pearson correlation test. The cumulative survival was 
computed using the Kaplan – Meier method. Survival 
time was calculated from the time of diagnosis to the 
date of death or the end of 2008. The effect of vari-
ables on the survival time was evaluated by Log Rank 
test. Stepped Cox regression test was used for the mul-
tivariate analyses. Differences with p < 0.05 were con-
sidered significant. 
 The ethics committee of King Abdul Aziz uni-
versity Hospital, Jeddah, Saudi Arabia approved this 
retrospective study without requiring patients' consent. 
 
RESULTS 
Malignant Astrocytoma (MAS) Statistics 
Total of 48 cases admitted to KAUH from January 
2004 to December 2008 were evaluated. 
 
Tumor Pathology: 
The number of AA was 15 (31.25%), all patients were 
confirmed with pathological studies. 
 The number of GBM was 33 (68.75%), all patients 
were confirmed with pathological studies. 
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Age 
The mean age for GBM was 55.3 ± 27.5 years. The 
mean age of AA was 27.4 ± 21.3 years. 
 There was a bimodal distribution of age where it 
peaks at age of 0-10 and between ages of 60-80 years. 
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Figure 1: Histogram shows the age distribution of MAS 
patients. 
 
Sex 
The number of male patients is 18 (37.5%) and the 
number of female patients is 30 (62.5%). 
 The male to female ratio is 1:1.6. 
 Number of male patients affected by glioblastoma 
multiforme (GBM) was 12 (66.67%) of all males in 
the study .The number of female patients affected by 
GBM was 21(70%) of all females in the study. 
 The number of male patients affected by AA was 
6 (33.3%) of all patients in the study. The number of 
female patients affected by anaplastic astrocytrma 
(AA) was 9 (30%) of all female patients. 
 About two thirds of the affected patients were 
females and about one third was males. 
 
Clinical Manifestations 
Symptoms 
The most common presenting symptom for Malignant 
astrocytoma (MAS) was headache 24 (50%) followed 
by seizure 12 (25%) and weakness 12 (25%). 
Signs 
The most common presenting sign for malignant astro-
cytoma was weakness 24 (50%) followed by abnormal 
reflexes 15 (31.25%). 
 
Duration of Symptoms 
The mean time for duration of symptoms was 1.4 ± 1 
month for anaplastic astrocytoma (AA) and 3.28±5.2 
months for GBM. 
 
Table 1: Count and percentage of the symptoms en-
countered with MAS. 
 
Symptom Count % 
Headache 24 50% 
Nausea   6 12.5% 
Vomiting    9 18.75% 
Seizure 12 25% 
Numbness   3 6.25% 
Weakness 12 25% 
Blurred vision   3 6.25% 
Unsteady gait   5 10.42% 
 
Table 2: Count and percentage of the signs encoun-
tered with MAS. 
 
Sign Count % 
Altered mental status 12 25.00% 
Weakness 24 50% 
Cranial nerve abnormality 12 25% 
Pupil abnormality    3 6.25% 
Coordination abnormality   3 6.25% 
Reflexes abnormality 15 31.25% 
Speech abnormality   3 6.25% 
 
Surgical Treatment 
All patients (48) underwent surgical interventions; 27 
(56.25%) biopsy only and 21 (43.75%) craniotomy for 
resection. The decision regarding which procedure to 
be performed depended on the patients’ level of con-
sciousness, the location of the tumor (superficial or 
deep) and radiological appearance of the mass (sug-
gestive of MAS or not). 
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Outcome 
The mean time of survival for anaplastic astrocytoma 
(AA) was 29.6 ± 22 months (95% CI18.4 – 40.7). The 
mean time of survival for the GBM is 4 ± 7.3 months 
(95% CI 1.4 – 6.5). 
 
Risk Factors 
Age:  The older the patient the worse the prognosis is. 
F (1, 46) = 0.3, p = .00002. 
 Where age of 46.6 (95% CI = 38.29 – 54.96) years 
was shown to be a demarcation age since patients < 
46.6 years survived more than one year and patients > 
46.6 years survived less than one year (95% CI = 6.76- 
17.24). 
 
 
Figure 2: Correlation between age (years) and survival 
(months). 
 
Vomiting presence worsens the prognosis r (48) = .3, p 
< .02. 
 Patients presented with vomiting survived less 
than one year (95% CI = 6.76 – 17.24), and patients 
presented without vomiting survived more than one 
year. 
Numbness presence worsened the prognosis r (45) = 
.64, p < .0001 
 Patients presented with numbness survived less 
than 10 nonths (95%CI = 4.8 – 15.2). 
Cranial nerves abnormalities worsen the prognosis r 
(48) = .49, p < .0004. 
 Patients presented with abnormal cranial nerves 
examination survived less than 10.2 months (95% CI = 
4.9 – 15.5). 
Abnormal mental status worsen the prognosis r (45) = 
.42, p < .003. 
 Patients presented with abnormal mental status 
examination survived less than 10.0 months (95% CI = 
4.8 – 15.3). 
 
Effect of Treatment on Survival 
Radiotherapy alone was an independent factor that 
prolong the survival of both types of MAS F (1, 46) = 
0.2, p = .0007. 
 For MAS the survival was affected significantly 
with combined treatment (surgery, chemotherapy and 
radiotherapy). χ2 (1, N = 48) = 8.64, p = .003. 
 
 
Survival (months) 
 
Figure 3: Kaplan – Meier survival curve showing the surv-
ival of AA (upper line) in comparison with GBM 
(lower line). 
 
DISCUSSION 
Gliomas are a heterogeneous group of neoplasm that 
comprises the majority of tumors originating in the 
central nervous system (CNS). In adults, the most fre-
quently encountered of these are high – grade or mali-
gnant neoplasms of astrocytic lineage, ie, anaplastic 
astrocytoma (AA) and glioblastoma multiforme 
(GBM).
5
 
 The current study focuses on the malignant astro-
cytomas only as they represent one of the most com-
mon primary brain tumors.
6,7
 
 It is shown in this study that the patients' age falls 
into bimodal distribution. It peaks in the first and sixth 
decades of life. For the adult population the age is con-
sistent with other study that showed almost the same 
age of involvement. The first decade of life involve-
ment is mainly due to brain stem malignant astrocy-
tomas. The patients ' age of anaplastic astrocytoma is 
significantly less than the GBM age (27 vs. 55 years) 
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that is consistent with another study that showed same 
results.
8
 However, in this study the difference is al-
most half of the age between the two groups. 
 The sex distribution is almost the same. This is 
different from most of the literature documentation, 
where the male predominance is common.
9
 This can 
be explained by the fact that the current study focuses 
only on the malignant astrocytomas without including 
other types of gliomas. However, this finding needs 
further evaluation. 
 The clinical presentation with headache and weak-
ness is due to either increased intracranial pressure or 
direct tumor invasion to the brain tissues. The clinical 
findings in this study are in concordance with other 
articles
10-13
 with this aspect. 
 The duration of symptoms shows less time period 
for the anaplastic astrocytoma by two months than 
GBM. This is the same range reported by the Tugcu 
et al.
6
 
 Age in this study is shown that younger patients 
survive longer than elderly patients, with patients less 
than forty six years survived more than one year. This 
finding is in line with the previously described litera-
ture.
14,15
 The author observed a pattern of declining 
survival rates in patients with increasing age of the 
patient, that is in consistence with other study.
16
 
 Patients presented with vomiting survived less 
than other patients with no vomiting. This finding is 
most likely due to either increased intracranial pres-
sure or brain stem invasion by the tumor. In either 
case, the survival is significantly affected due to fata-
lity of both possibilities. 
 Presence of numbness affected the survival signi-
fi-cantly. Where patients presented with numbness 
survived less than ten months. 
 Abnormal Mental status affects the survival. 
Patients with low mini mental status score survived 
less than normal mini mental status ones. This is a well 
established prognostic factor in the literature.
17-19
 The 
current paper confirms this finding in our patients’ 
population. 
 Abnormal cranial nerves upon admission worsen 
the prognosis. Patients with abnormal cranial nerves 
examination survived less than 10.2 months in compa-
rison with intact cranial nerves. It is possible to be 
related to increased intracranial pressure or brain stem 
involvement. 
 Combined treatment with surgery, chemotherapy 
and radiotherapy prolonged the survival significantly 
that is well known in the literature.
20-23
 
 This is a retrospective study. Keeping in mind that 
this study focuses on clinical risk factors only, so fol-
low up of the study cohort is not essential. However, a 
prospective study will increase the power of the evi-
dence level of the findings in this article. 
 The patient’s number limitation in this study re-
presents a single institution experience. More patients 
can be recruited by conducting a multicentre study. 
 The Kanofsky performance scale is not empha-
sized on in this article, as it was well studied in other 
papers.
24-27
 It is highly recommended to adopt a pati-
ents performance scale assessment upon admission of 
the patients to unify different assessment methods in 
the hospital, which is adopt it in many articles.
28-32
 
 This article may help the health care provider(s) to 
predict the survival of patients with MAS preopera-
tively. However, using advanced techniques will incre-
ase the accuracy of this prediction.
33
 
 
CONCLUSION 
Clinical risk factors affecting survival negatively of 
patients with malignant astrocytomas at King Abdul 
Aziz university hospital are age, presentation with 
vomiting, numbness, abnormal mental status and 
abnormal cranial nerves examination. 
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